Treating Restless Leg Syndrome with Ferric Carboxymaltose

Treating Restless Leg Syndrome with Ferric Carboxymaltose is organized by Connect Educate Impact (CEI).

Initial Release Date: February 9, 2022
Planned Expiration Date: February 9, 2025 

Description:
This month we are dissecting an article from Sleep Medicine, the official journal of the World Sleep Society and International Pediatric Sleep Association - in a Randomized, placebo-controlled trial of ferric carboxymaltose in restless legs syndrome patients with iron deficiency anemia. Treatment guidelines for Restless Leg Syndrome (RLS) advocate for using iron therapy when peripheral iron levels are low, however, they don't address treatment with concomitant iron deficiency anemia. Join us for this month's Journal Club as we evaluate iron studies and recommend appropriate oral/parenteral iron doses and frequency for RLS.

Objectives:
Upon successful completion of this application-based course, participants should be able to:
• Evaluate the clinical and statistical significance of a study examining the use of Ferric carboxymaltose (FCM) in patients with Restless Leg Syndrome (RLS) and concomitant Iron Deficiency Anemia (IDA)
• Determine appropriate laboratory tests (iron indices) which may be used to identify patients with IDA and RLS who are candidates for a trial of FCM administration
• Use a validated scale to assess patient response to FCM when used to treat RLS + IDA
• Create a treatment regimen for a patient with RLS + IDA using FCM

Additional Details Will Be Posted as Soon as Information is Available.

0.1 CEU